Current oncology最新文献

筛选
英文 中文
The Role of Stereotactic Body Radiotherapy in Oligometastatic Non-Small Cell Lung Cancer.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-15 DOI: 10.3390/curroncol31120588
Benson Wan, Magali Lecavalier-Barsoum
{"title":"The Role of Stereotactic Body Radiotherapy in Oligometastatic Non-Small Cell Lung Cancer.","authors":"Benson Wan, Magali Lecavalier-Barsoum","doi":"10.3390/curroncol31120588","DOIUrl":"10.3390/curroncol31120588","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) is a major cause of mortality in Canada, with many patients presenting with metastatic disease. The oligometastatic state (OM-NSCLC) may be amenable to cure using aggressive local consolidative therapies. Stereotactic body radiotherapy (SBRT), which entails the utilization of a high dose of radiation in one or few fractions, has many benefits in this setting, including its applicability in varied patient populations to ablate lesions in varied anatomical locations. It has also been demonstrated to prolong the time to next-line systemic therapy, to reduce financial burden, to improve quality-adjusted life years, and reduce adverse events caused by these lesions. This review outlines the published phase II and III trials that have already demonstrated the utility of SBRT in OM-NSCLC, as well as the many ongoing trials aiming to further define its role, including the largest phase II/III trial to date, NRG-LU002. Overall, SBRT appears to improve outcomes when combined with a broad range of standard-of-care therapies and is generally well tolerated; however, careful patient selection is necessary to maximize benefits while minimizing harm. Ongoing trials will help define the optimal patients for SBRT and the best timing for this intervention.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7971-7978"},"PeriodicalIF":2.8,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Influence of Nordic Walking Training on the Serum Levels of Sirtuins, FOXO3a, and Vitamin D Metabolites in Patients with Multiple Myeloma.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-14 DOI: 10.3390/curroncol31120587
Olga Czerwińska-Ledwig, Małgorzata Żychowska, Artur Jurczyszyn, Joanna Kryst, Adrianna Dzidek, Roxana Zuziak, Anna Jurczyszyn, Anna Piotrowska
{"title":"The Influence of Nordic Walking Training on the Serum Levels of Sirtuins, FOXO3a, and Vitamin D Metabolites in Patients with Multiple Myeloma.","authors":"Olga Czerwińska-Ledwig, Małgorzata Żychowska, Artur Jurczyszyn, Joanna Kryst, Adrianna Dzidek, Roxana Zuziak, Anna Jurczyszyn, Anna Piotrowska","doi":"10.3390/curroncol31120587","DOIUrl":"10.3390/curroncol31120587","url":null,"abstract":"<p><strong>Background: </strong>Multiple myeloma, a malignancy of plasma cells, often involves the disruption of vitamin D metabolism. Vitamin D, acting through its receptor (VDR), affects transcription factors like FOXO and sirtuins, which regulate cellular processes. The impact of physical activity on these markers in multiple myeloma patients is unclear. Therefore, the objective of this study was to evaluate the effects of a 6-week training program on these parameters.</p><p><strong>Material and methods: </strong>The study was completed by 30 patients, including 16 in the Nordic walking training group (TG) and 14 in the control group (non-exercising, CG). All participants underwent a thorough medical interview before starting the project. Venous blood samples were collected from all participants four times-at baseline, after 3 weeks, after 6 weeks, and after 9 weeks (follow-up). The serum concentrations of sirtuin 1, sirtuin 3, Foxo3a, vitamin D receptor (VDR), 25(OH)D3, and 1,25(OH)2D were determined. Body composition, physical fitness, and physical activity level were assessed at baseline and after 6 weeks.</p><p><strong>Results: </strong>No statistically significant changes were observed in the serum levels of sirtuins, the FOXO3a protein, and 1,25(OH)2D. A statistically significant difference was observed in the levels of VDR for both time and group factors, but this was not confirmed in the post hoc test. Vitamin 25(OH)D3 level increased significantly in the study group with time.</p><p><strong>Conclusions: </strong>The applied 6-week Nordic walking training cycle positively affected the level of vitamin 25(OH)D3 but did not influence the rest of the biochemical parameters studied. The obtained results also indicate that the applied intervention is safe for patients and does not interfere with body composition.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7960-7970"},"PeriodicalIF":2.8,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Education and Training Needs of Health Care Professionals in the Philippines Encountering Patients with Lung Oligometastatic Cancers.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-13 DOI: 10.3390/curroncol31120586
Daphne J Valmonte, Naa Kwarley Quartey, Fatima Gutierrez, Janel Mendoza, Janet Papadakos, Meredith Giuliani
{"title":"Education and Training Needs of Health Care Professionals in the Philippines Encountering Patients with Lung Oligometastatic Cancers.","authors":"Daphne J Valmonte, Naa Kwarley Quartey, Fatima Gutierrez, Janel Mendoza, Janet Papadakos, Meredith Giuliani","doi":"10.3390/curroncol31120586","DOIUrl":"10.3390/curroncol31120586","url":null,"abstract":"<p><p>This study aimed to examine the education and training needs of health care practitioners (HCPs) in the Philippines who encounter lung oligometastatic cancer patients. Lung oligometastatic disease is among the most common sites for cancer spread and has the most established practices for treating oligometastases. A modified version of the Hennessy-Hicks Training Needs Assessment Questionnaire was administered online to HCPs working in private and public centers in the Philippines. HCPs were recruited via purposive sampling. Twenty-seven HCPs completed the questionnaire (47% response rate). Respondents were mostly female (59%) and between the ages of 30 and 39 years (70%). Three-quarters (74%) were consultants, and most respondents were radiation oncologists (44%) or medical oncologists (30%). Medical oncologists rated Management/Supervisory Tasks (mean = 1.42) as their highest area of training need while radiation oncologists rated Clinical Tasks (mean = 1.30) as their highest training need. Pulmonologists (mean = 0.60) and other specialists (mean = 1.00) rated Administration tasks as their top area of training need. The clinical task-related category was rated the highest need among the continuing medical education topics. This study provides valuable insights for the implementation and advancement of a comprehensive curriculum in clinical oncology, specifically designed to enhance the administrative, clinical, and research capacities of oncologists who encounter oligometastatic lung disease in the Philippines.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7950-7959"},"PeriodicalIF":2.8,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Clinical Characteristics of a Stage II Colorectal Cancer T4 Tumor: A Ten-Year Single-Center Research Report.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-12 DOI: 10.3390/curroncol31120584
Bo-Zhi Lin, Chang-Lin Lin, Feng-Fan Chiang, Chou-Chen Chen, Ming-Cheng Chen, Chun-Yu Lin, Shang-Chih Huang
{"title":"The Clinical Characteristics of a Stage II Colorectal Cancer T4 Tumor: A Ten-Year Single-Center Research Report.","authors":"Bo-Zhi Lin, Chang-Lin Lin, Feng-Fan Chiang, Chou-Chen Chen, Ming-Cheng Chen, Chun-Yu Lin, Shang-Chih Huang","doi":"10.3390/curroncol31120584","DOIUrl":"10.3390/curroncol31120584","url":null,"abstract":"<p><strong>Aim: </strong>The tumor staging of colorectal cancer (CRC) plays a significant role in both treatment and prognosis, impacting surgical planning and adjuvant therapy decisions. Currently, the staging of CRC is based on the TNM system developed by the American Joint Committee on Cancer. Prior studies have suggested that survival rates and recurrent rates of T4a tumors appear to be worse than that of T4b tumors, although there is currently no consensus. Therefore, we collected patient data from Taichung Veterans General Hospital over the past decade in order to conduct further research.</p><p><strong>Method: </strong>Between 2010 and 2018, a total of 5760 newly diagnosed CRC patients were seen at the hospital. To eliminate the influence of any local lymph node involvement or distant organ metastasis on the research results, we focused on patients with pathologic Stage IIc disease (T4a-bN0M0). Patients with rectal cancer who had received neoadjuvant concurrent chemoradiotherapy were excluded. Ultimately, 132 patients were included in this study. A multivariate Cox regression analysis was conducted to identify independent risk factors for both 10-year cancer-specific survival (CSS) and overall survival (OS).</p><p><strong>Results: </strong>A total of 132 patients were included in the study, with 90 classified as T4a and 42 as T4b. The 10-year CSS for pT4a and pT4b was 72.5% and 56.5%, respectively, with a <i>p</i>-value of 0.011. The 10-year OS for pT4a and pT4b was 48.4% and 42.5%, respectively, with a <i>p</i>-value of 0.086. There was no significant difference in the site of first recurrence between the pT4a and pT4b groups (<i>p</i>-value = 0.936). Overall, patients who received adjuvant chemotherapy therapy had a significantly better prognosis (<i>p</i>-value < 0.05). However, there was no significant difference in prognosis between oral 5-FU and FOLFOX.</p><p><strong>Conclusion: </strong>Based on our data, patients diagnosed with pathologic T4aN0M0 CRC appeared to experience a trend toward better 10-year OS when compared to those with T4bN0M0 disease, but this trend lacks statistical significance. Patients with locally advanced Stage II colon cancer clearly benefited from adjuvant chemotherapy therapy; therefore, FOLFOX may not necessarily be required.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7924-7935"},"PeriodicalIF":2.8,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
STIL Overexpression Is Associated with Chromosomal Numerical Abnormalities in Non-Small-Cell Lung Carcinoma Through Centrosome Amplification.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-12 DOI: 10.3390/curroncol31120585
Shunsuke Ohtsuka, Hisami Kato, Rei Ishikawa, Hirofumi Watanabe, Ryosuke Miyazaki, Shin-Ya Katsuragi, Katsuhiro Yoshimura, Hidetaka Yamada, Yasuhiro Sakai, Yusuke Inoue, Yusuke Takanashi, Keigo Sekihara, Kazuhito Funai, Haruhiko Sugimura, Kazuya Shinmura
{"title":"STIL Overexpression Is Associated with Chromosomal Numerical Abnormalities in Non-Small-Cell Lung Carcinoma Through Centrosome Amplification.","authors":"Shunsuke Ohtsuka, Hisami Kato, Rei Ishikawa, Hirofumi Watanabe, Ryosuke Miyazaki, Shin-Ya Katsuragi, Katsuhiro Yoshimura, Hidetaka Yamada, Yasuhiro Sakai, Yusuke Inoue, Yusuke Takanashi, Keigo Sekihara, Kazuhito Funai, Haruhiko Sugimura, Kazuya Shinmura","doi":"10.3390/curroncol31120585","DOIUrl":"10.3390/curroncol31120585","url":null,"abstract":"<p><p>STIL is a regulatory protein essential for centriole biogenesis, and its dysregulation has been implicated in various diseases, including malignancies. However, its role in non-small-cell lung carcinoma (NSCLC) remains unclear. In this study, we examined STIL expression and its potential association with chromosomal numerical abnormalities (CNAs) in NSCLC using The Cancer Genome Atlas (TCGA) dataset, immunohistochemical analysis, and in vitro experiments with NSCLC cell lines designed to overexpress STIL. TCGA data revealed upregulated STIL mRNA expression in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), the two major subtypes of NSCLC. Immunohistochemical analysis of cases from our hospital (LUAD, <i>n</i> = 268; LUSC, <i>n</i> = 98) revealed STIL protein overexpression. To elucidate the functional role of STIL, an inducible STIL-overexpressing H1299 NSCLC cell line was generated. Overexpression of STIL in these cells promoted centrosome amplification, leading to chromosomal instability. Finally, analysis of arm-level chromosomal copy number alterations from the TCGA dataset revealed that elevated STIL mRNA expression was associated with CNAs in both LUAD and LUSC. These findings suggest that STIL overexpression is associated with CNAs in NSCLC, likely through centrosome amplification, which is linked to chromosomal instability and might represent a potential therapeutic target for NSCLC treatment.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7936-7949"},"PeriodicalIF":2.8,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal Follow-Up of the Psychological Well-Being of Patients with Colorectal Cancer: Final Analysis of PICO-SM.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-11 DOI: 10.3390/curroncol31120582
Konstantinos Kamposioras, Panagiotis Ntellas, Katerina Dadouli, Eleftherios Christodoulis, Marios Adamou, Daniel Anderson, Anup Shanthappa, Jacqueline Connell, Joseph Williams, Lilly Simpson, Theodora Germetaki, Michael Braun, Jorge Barriuso, Jurjees Hasan, Saifee Mullamitha, Kalena Marti, Mark Saunders, Kok Haw Jonathan Lim
{"title":"Longitudinal Follow-Up of the Psychological Well-Being of Patients with Colorectal Cancer: Final Analysis of PICO-SM.","authors":"Konstantinos Kamposioras, Panagiotis Ntellas, Katerina Dadouli, Eleftherios Christodoulis, Marios Adamou, Daniel Anderson, Anup Shanthappa, Jacqueline Connell, Joseph Williams, Lilly Simpson, Theodora Germetaki, Michael Braun, Jorge Barriuso, Jurjees Hasan, Saifee Mullamitha, Kalena Marti, Mark Saunders, Kok Haw Jonathan Lim","doi":"10.3390/curroncol31120582","DOIUrl":"10.3390/curroncol31120582","url":null,"abstract":"<p><p>PICO-SM was a prospective longitudinal study investigating the psychological impact of the COVID-19 pandemic on patients with colorectal cancer treated in a large UK tertiary cancer centre. Here, we present the impact of the third wave of the pandemic (December 2021 to February 2022), when the Omicron variant became prevalent in the UK, and the complete longitudinal comparison across the entire duration of this study. Patients were invited to complete a questionnaire, including screening psychometric tools. In total, n = 312 patients were included in the final analysis. Specifically, in this Omicron-predominant wave, n = 96 patients were studied in detail: the mean age was 64 years, 64% were male, 33% reported poor well-being, 27% anxiety, 11% depressive symptoms, and 3% trauma-related symptoms. The participants who had investigations cancelled (OR 9.22, 95% CI 1.09-77.85; <i>p</i> = 0.041) or felt that the pandemic would affect their mental health (OR 3.82, 95% CI 1.96-7.44; <i>p</i> < 0.001) had an increased risk of anxiety according to a multivariate analysis. Similarly, independent predictors of poor well-being included concern that the pandemic would affect their cancer treatment (OR 4.59, 95% CI 1.03-20.56; <i>p</i> = 0.046) or mental health (OR 3.90, 95% CI 1.38-11.03; <i>p</i> = 0.010). The psychological distress experienced by patients, particularly anxiety, remained high during the third wave of the COVID-19 pandemic. These results align with our previously reported findings, emphasising the importance of continuing cancer treatment amidst an ongoing humanitarian emergency.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7903-7913"},"PeriodicalIF":2.8,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-11 DOI: 10.3390/curroncol31120583
Tomoki Taniguchi, Koji Iinuma, Kei Kawada, Takashi Ishida, Kimiaki Takagi, Masayuki Tomioka, Makoto Kawase, Kota Kawase, Keita Nakane, Yuki Tobisawa, Takuya Koie
{"title":"Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan.","authors":"Tomoki Taniguchi, Koji Iinuma, Kei Kawada, Takashi Ishida, Kimiaki Takagi, Masayuki Tomioka, Makoto Kawase, Kota Kawase, Keita Nakane, Yuki Tobisawa, Takuya Koie","doi":"10.3390/curroncol31120583","DOIUrl":"10.3390/curroncol31120583","url":null,"abstract":"<p><p>A combination of nivolumab and ipilimumab (NIVO + IPI) is the only approved combination of two immune checkpoint inhibitors for metastatic or advanced renal cell carcinoma (mRCC). Inadequate evidence of treatment with NIVO + IPI has been reported in Japanese cohorts. We evaluated the clinical efficacy of NIVO + IPI treatment. Patients with mRCC who received NIVO + IPI at nine Japanese facilities between August 2018 and March 2023 were enrolled in this study. The primary endpoint in this study was the assessment of oncological outcomes in patients with mRCC who received NIVO + IPI. Eighty-four patients with mRCC were enrolled. The median follow-up period was 18.3 months, and median progression-free and overall survival were 13.3 and 50.9 months, respectively. The objective response rate was 47.6%, and the disease control rate was 78.6%. To our knowledge, this is the largest study that evaluates Japanese patients with mRCC receiving NIVO + IPI treatment. In this study, the real-world oncological outcomes after NIVO + IPI treatment were comparable to those in the CheckMate 214 study.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7914-7923"},"PeriodicalIF":2.8,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-09 DOI: 10.3390/curroncol31120581
Guillermo Valencia, Patricia Rioja, Miguel Chirito, Olenka Peralta, Jorge Sánchez, Connie Rabanal, Raúl Mantilla, Zaida Morante, Hugo Fuentes, Carlos Castaneda, Tatiana Vidaurre, Cristian Pacheco, Silvia Neciosup, Henry L Gomez
{"title":"First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution.","authors":"Guillermo Valencia, Patricia Rioja, Miguel Chirito, Olenka Peralta, Jorge Sánchez, Connie Rabanal, Raúl Mantilla, Zaida Morante, Hugo Fuentes, Carlos Castaneda, Tatiana Vidaurre, Cristian Pacheco, Silvia Neciosup, Henry L Gomez","doi":"10.3390/curroncol31120581","DOIUrl":"10.3390/curroncol31120581","url":null,"abstract":"<p><p>Advanced breast cancer is an incurable disease, with a median overall survival of 3 years, including in countries without access problems. Although chemotherapy is reserved in some cases, it is still used in many countries as a first-line therapy. The aim of our study is to evaluate the first-line treatment choices and the factors that influence therapeutic decisions. A retrospective analysis was conducted of hormone receptor (+)/HER2 (-) advanced breast cancer patients classified into three groups according to the first-line and second-line treatment received: endocrine therapy-chemotherapy, endocrine therapy-endocrine therapy and chemotherapy-endocrine therapy. Additionally, we explored the overall survival of sequencing therapy groups. First-line chemotherapy was chosen in 34% of patients. Also, around 60% of our patients met the \"aggressive disease\" criteria from the RIGHT Choice trial, justifying the use of chemotherapy in a population with poor prognosis. Furthermore, de novo and progressive disease were prognostic factors that influenced the use of chemotherapy as a first-line treatment. Regarding overall survival, the sequencing treatment groups in this trial saw an increase in survival compared with patients of the MONALEESA trials (endocrine therapy alone arms). No significant differences in progression-free survival or overall survival were found in the treatment sequencing groups. There was a higher use of chemotherapy as a first-line therapy, with de novo and \"aggressive disease\" criteria being the main factors to influence the decision.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7890-7902"},"PeriodicalIF":2.8,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing Barriers to Cancer Screening and Early Detection in Older Adults in Saudi Arabia: A Mixed-Methods Approach to Oncology Nursing Practice Implications.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-08 DOI: 10.3390/curroncol31120580
Abdulaziz M Alodhialah, Ashwaq A Almutairi, Mohammed Almutairi
{"title":"Assessing Barriers to Cancer Screening and Early Detection in Older Adults in Saudi Arabia: A Mixed-Methods Approach to Oncology Nursing Practice Implications.","authors":"Abdulaziz M Alodhialah, Ashwaq A Almutairi, Mohammed Almutairi","doi":"10.3390/curroncol31120580","DOIUrl":"10.3390/curroncol31120580","url":null,"abstract":"<p><strong>Background: </strong>Access to cancer screening services is crucial for early detection and improved survival rates, yet older adults in Saudi Arabia face significant barriers. Recent data from the Saudi Health Ministry indicate that cancer incidence in this demographic is rising, underscoring the urgent need for enhanced screening efforts. This study explores the factors influencing cancer screening behaviors among older adults in Riyadh, using a mixed-methods approach to identify and address these barriers effectively.</p><p><strong>Methods: </strong>The study integrated quantitative data from 100 participants aged 60 and above who attended King Saud University-affiliated healthcare centers, and qualitative insights from 20 semi-structured interviews. The Barriers to Cancer Screening Scale (BCSS) quantitatively assessed barriers, while the thematic analysis of interview data helped identify key themes.</p><p><strong>Results: </strong>Findings revealed significant barriers, categorized into three primary themes: accessibility challenges, psychological barriers, and social influences. These include logistical difficulties related to transportation and service availability, fears and anxieties regarding cancer diagnoses, and a lack of family support and cultural stigma, all of which impact participants' willingness to engage in screening.</p><p><strong>Conclusion: </strong>The study underscores the multifaceted barriers faced by older adults in accessing cancer screening in Saudi Arabia. Tailored interventions that address logistical, psychological, and social factors are essential to enhance screening uptake and ensure equitable access to preventive services. These findings contribute to the ongoing discussions on public health strategies and underscore the necessity for community and healthcare provider engagement to improve cancer screening rates in this population.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7872-7889"},"PeriodicalIF":2.8,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the American College of Surgeons Surgical Risk Calculator (ACS-SRC) for Prediction of Early Postoperative Complications in Patients Undergoing Cytoreductive Surgery for Ovarian Peritoneal Carcinomatosis.
IF 2.8 4区 医学
Current oncology Pub Date : 2024-12-07 DOI: 10.3390/curroncol31120579
Cedric Kabeya, Charif Khaled, Laura Polastro, Michel Moreau, Dario Bucella, Maxime Fastrez, Gabriel Liberale
{"title":"Assessment of the American College of Surgeons Surgical Risk Calculator (ACS-SRC) for Prediction of Early Postoperative Complications in Patients Undergoing Cytoreductive Surgery for Ovarian Peritoneal Carcinomatosis.","authors":"Cedric Kabeya, Charif Khaled, Laura Polastro, Michel Moreau, Dario Bucella, Maxime Fastrez, Gabriel Liberale","doi":"10.3390/curroncol31120579","DOIUrl":"10.3390/curroncol31120579","url":null,"abstract":"<p><p>Ovarian cancer (OC) is diagnosed at a locally advanced stage in two-thirds of cases. The first line of treatment consists of cytoreductive surgery (CRS) combined with neoadjuvant and/or adjuvant chemotherapy. However, CRS can be associated with high rates of postoperative complications (POCs), and detection of fragile patients at high risk of POCs is important. The American College of Surgeons Surgical Risk Calculator (ACS-SRC) provides a predictive model for early POCs (30 days) for any given surgical procedure. This study aimed to evaluate the performance of the ACS-SRC in predicting the occurrence of early POCs for patients undergoing CRS for OC. This was a retrospective study that included patients undergoing CRS for advanced OC between January 2010 and December 2022. Early POCs were reviewed, and the rate of POCs was compared with those predicted by the ACS-SRC to evaluate its accuracy (i.e., discrimination and calibration). A total of 218 patients were included, 112 of whom underwent extensive surgery/resection. A total of 94 complications were recorded. This cohort demonstrated correct calibration of the ACS-SRC for the prediction of surgical site infection, readmission, and the need for nursing care post-discharge (NCPD; transfer to revalidation center or need for nursing care at home). Using both the discrimination and calibration methods, the score only predicted NCPD. In this study, the ACS-SRC was shown to be of little value for patients undergoing cytoreductive surgery for ovarian peritoneal carcinomatosis, as it only accurately predicted NCPD.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7863-7871"},"PeriodicalIF":2.8,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信